NASDAQ:BBIO

Bridgebio Pharma Stock Insider Trading

Healthcare > Biotechnology

Buy BBIO

*Your capital is at risk

$80.09

-2.05 (-2.50%)

At Close: Jul 31, 2026

Bridgebio Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -85.03. In total, the insiders bought 851.27K and sold 562.47K BBIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-85.03
● Buy	851.27K shares
● Sell	562.47K shares
52% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Jul 09, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -85.03. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Homcy Charles J Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Aguiar Eric Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Aguiar Eric Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Common Stock A-Award	Dachille Douglas A. Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Cook Jennifer E. Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock M-Exempt	Valantine Hannah Director	Director	2 808 Value: $117.2K
Jun 22, 2026 Buy	Common Stock A-Award	Valantine Hannah Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Common Stock A-Award	Daniels Ronald J Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Lo Andrew Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Homcy Charles J Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Satvat Ali J. Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Dachille Douglas A. Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Satvat Ali J. Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Daniels Ronald J Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Ellis Andrea Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Ellis Andrea Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Hassan Fred Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Hassan Fred Director	Director	5 277 Value: $363.7K
Jun 22, 2026 Buy	Common Stock A-Award	Momtazee James C Director	Director	3 990 Value: $275.0K
Jun 22, 2026 Buy	Common Stock A-Award	Cook Jennifer E. Director	Director	3 990 Value: $275.0K
Jun 20, 2026 Sell	Common Stock F-InKind	Homcy Charles J Director	Director	788 Value: $52.2K
Jun 15, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Cook Jennifer E. Director	Director	65 921 Value: $557.0K
Jun 15, 2026 Buy	Common Stock M-Exempt	Cook Jennifer E. Director	Director	17 167 Value: $287.5K
Jun 15, 2026 Buy	Common Stock M-Exempt	Cook Jennifer E. Director	Director	65 921 Value: $557.0K
Jun 15, 2026 Sell	Common Stock S-Sale	Cook Jennifer E. Director	Director	1 503 Value: $100.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BRIDGEBIO PHARMA INC.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...

Read Full Profile Here